Prot#WN43194: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab as Monotherapy or in Addition to Baseline Therapy in Patients with Myelin O

Project: Research project

Project Details

StatusActive
Effective start/end date5/18/225/18/25

Funding

  • Genentech, Inc (Prot#WN43194/Amend # 2)